Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995

Human Reproduction Update

Volumn 6, Issue 5, 2000, Pages 419-426

  Doren M ^a   Samsioe, G ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density; Hormone replacement therapy; Prevention of osteoporosis; Progestogen; Selective oestrogen receptor modulators

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTRIOL SUCCINATE; ESTROGEN; ETIDRONIC ACID; FLUOROPHOSPHATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PARATHYROID HORMONE; PLACEBO; PROGESTERONE; PROGESTERONE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

AGE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECT; DRUG FORMULATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; RISK BENEFIT ANALYSIS; TRANSDERMAL PATCH; VERTEBRA FRACTURE;

EID: 0033809982     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/6.5.419     Document Type: Review

References (94)

1. Prevention of bone loss in postmenopausal women by norethisterone
2. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy
3. Continuous combined hormone replacement therapy compared with tibolone
4. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study
5. Hormone replacement therapy, heart disease, and other considerations
6. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: A two-year randomised controlled trial
7. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study
8. Tibolone: Prevention of bone loss in late postmenopausal women
9. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
10. Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function
11. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
12. Prevention of falls in the elderly trial (PROFET). A randomised controlled trial
13. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women
14. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
15. Prophylaxis and treatment of osteoporosis
16. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
17. The effect of raloxifene on risk of breast cancer in postmenopausal women
18. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
19. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
20. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women
21. Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women
22. Hormonal replacement regimens and bleedings
23. The impact of different HRT regimens on compliance
24. Superior compliance and efficacy of continuously combined oral estrogen-progestogen replacement therapy in postmenopausal women
25. Impact on uterine bleeding and endometrial thickness - Tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy
26. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women
27. Classification of vertebral fractures
28. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women
29. Personal perspective on low-dosage estrogen therapy for postmenopausal women
30. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
31. Human Menopause Society
32. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
33. Moderation of the daily dose of HRT: Prevention of osteoporosis
34. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
35. 3
36. Hormone therapy to prevent disease and prolong life in postmenopausal women
37. Hormone replacement therapy and endometrial cancer: A meta-analysis
38. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
39. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
40. Preservation of bone mass in postmenopausal women during therapy with estrogen and progestogens
41. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995
42. Effects of transdermal oestrogen therapy in postmenopausal women: A comparative study of an oestradiol gel and an oestradiol delivering patch
43. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
44. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
45. 3 and calcium lactate on vertebral bone loss in early menopausal women
46. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate
47. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial
48. 3 in early postmenopausal women: A population-based 5-year randomized trial
49. Ups and downs for HRT and heart disease
50. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss
51. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding (Cochrane Review)
52. Bone loss during oestriol therapy in postmenopausal women
53. Prevention of spinal osteoporosis in oophorectomised women
54. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
55. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
56. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dydrogesterone
57. Treatment of postmenopausal osteoporosis with transdermal estrogen
58. Prevention of postoophorectomy bone loss with tibolone
59. Meta-analysis about efficacy of anti-resorptive drugs in postmenopausal osteoporosis
60. Breast cancer risk following long-term oestrogen- And oestrogen-progestin-replacement therapy
61. The assessment of vertebral deformity. A method for use in population studies and clinical trials
62. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene
63. Hormone replacement therapy and risk of hip fracture: Population based case-control study
64. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-1, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin
65. Effect of estriol on bone mass loss in postmenopausal Japanese women: A multicentric prospective open study
66. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
67. Estrogen replacement therapy I: A 10-year prospective study in the relationship to osteoporosis
68. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis
69. Usefulness of estriol for the treatment of bone loss in postmenopausal women
70. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects
71. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen
72. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures
73. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
74. Estrogen-progestin replacement therapy and endometrial cancer
75. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
76. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
77. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women
78. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis
79. Effects of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
80. Hormone replacement therapy: Aspects of bleeding problems and compliance
81. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
82. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study)
83. A double-blind, double-dummy, comparative study of Menorest 50® versus Premarin® 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms
84. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
85. Clinical profile of Org OD14
86. Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
87. A 3-year study of prevention of postmenopausal bone loss: Conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone
88. Combined continuous hormone replacement therapy: A critical review
89. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
90. Low-potency oestrogen and risk of endometrial cancer: A case-control study
91. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss
92. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrate: Four-year randomized study
93. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis